Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890390 | 0.89 | LMNA (0.46) | BACE1BACE2LMNAPLGPLAT | |
| SCHEMBL159817 | 0.89 | LMNA (0.46) | BACE1BACE2LMNAPLGPLAT | |
| Hydrochloric Acid SCHEMBL25415692 | 0.88 | LMNA (0.44) | BACE1BACE2LMNAPLGPLAT | |
| SCHEMBL28102949 | 0.84 | BACE1 (0.36) | BACE1BACE2LMNAPLGPLAT | |
| SCHEMBL28063070 | 0.84 | BACE1 (0.36) | BACE1BACE2LMNAPLGPLAT | |
| Succinic Acid SCHEMBL23234379 | 0.84 | PTGS1 (0.42) | BACE1BACE2LMNAPLGPLAT | |
| Succinimide SCHEMBL9845552 | 0.83 | BACE1 (0.41) | BACE1BACE2LMNAPLGPLAT | |
| SCHEMBL16552327 | 0.81 | PLG (0.47) | BACE1BACE2LMNAPLGPLAT | |
| SCHEMBL535579 | 0.81 | PLG (0.47) | BACE1BACE2LMNAPLGPLAT | |
| SCHEMBL28880603 | 0.80 | ANPEP (0.41) | BACE1BACE2LMNAPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108226467-B | Reversible cell labeling using conjugates with two releasable binding sites | 美天施生物科技有限两合公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114616458-A | Serial multi-channel microscopy | 美天施生物科技有限两合公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-113748217-A | Systems, compositions, and methods for target entity detection | 仁慈生物分析公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113677995-A | Reversible cell detection using conjugates with linkers for increasing fluorescence brightness and enzymatically releasable fluorescent moieties | 美天施生物科技有限两合公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021101349-A1 | ANTIBODY THAT BINDS TO ROR1 AND B7-H3, ANTIBODY-DRUG CONJUGATE CONTAINING SAME, AND USE THEREOF | 에이비엘바이오 주식회사 | 2021-05-27 | — | — | WO | disclosed |
| CN-106170564-B | Proximity assays based on detection of Hybrid Chain Reaction (HCR) | 欧凌科生物科技公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10031137-B2 | Devices, methods, and kits for detecting an analyte in a sample | DREXEL UNIVERSITY (US) | 2018-07-24 | — | — | US | disclosed |
| US-20080213266-A1 | Method for Treating CCR4-Related Diseases | KYOWA HAKKO KOGYO CO., LTD. | 2008-09-04 | — | — | US | disclosed |
| EP-1266032-B1 | FUNCTIONALIZED ENCAPSULATED FLUORESCENT NANOCRYSTALS | BIOCRYSTAL LTD (US) | 2008-01-09 | — | — | EP | disclosed |
| US-5063109-A | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents | ABBOTT LABORATORIES (US) | 1991-11-05 | — | — | US | disclosed |
| US-5002883-A | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents | ABBOTT LABORATORIES (US) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213266-A1 | Method for Treating CCR4-Related Diseases | CCR4, CCR1, CCR6 | BACE1 4415/4885BACE2 4765/4885LMNA 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.